Talicia Global Acquisition
Apotex acquires full global ownership of Talicia in a $53 million deal with RedHill.
Anonymous
Key Points
1
RedHill's late-stage GI-focused pipeline includes opaganib (for Ebola-related and radiation indications), RHB-102, RHB-204 and RHB-107.
2
The Talicia divestiture was announced on Aug. 31, 2026, with Apotex paying $18 million upfront and up to $35 million in worldwide net sales milestone payments; the deal follows Apotex's prior acquisition of Cumberland Pharmaceuticals' 30% stake in THI.
3
RedHill's CEO Dror Ben-Asher described the deal as converting Talicia into immediate capital, creating stronger liquidity and meaningful upside to fund RedHill's next phase of commercial expansion.
4
Analyst commentary from TipRanks notes RedHill (RDHL) as Neutral, citing severely weakened financial performance, ongoing losses and persistent cash burn as drivers of negative momentum despite oversold signals.
RedHill Biopharma sold its 70% stake in Talicia to Apotex Health for $18 million upfront, plus up to $35 million in worldwide milestone payments. The deal gives Apotex full global ownership of the H. pylori treatment after it earlier acquired the remaining 30% stake from Cumberland Pharmaceuticals. Morning Chronicle reported the announcement on August 31, 2026.
RedHill CEO Dror Ben-Asher called the deal a way to convert Talicia into immediate cash. The company plans to use the liquidity to fund its next phase of growth and move closer to profitability. GuruFocus noted RedHill is now refocusing on gastrointestinal drugs, infectious diseases, and oncology with a late-stage pipeline that includes opaganib, RHB-102, RHB-204, and RHB-107.
Why RedHill Needed the Cash Injection
RedHill has faced severe financial headwinds. The company posted ongoing losses and persistent cash burn that weakened its balance sheet. TipRanks rated RedHill as Neutral, citing weak financial performance despite some oversold signals. The Talicia sale gives the company breathing room to fund its pipeline without immediate fundraising pressure.
Apotex Consolidates Full Control of H. Pylori Drug
Apotex now owns all of Talicia after acquiring RedHill's 70% stake and Cumberland Pharmaceuticals' 30% stake. The deal gives Apotex exclusive global rights to commercialize the H. pylori treatment. MarketWatch reported Apotex will pay up to $53 million total — $18 million upfront plus milestone payments tied to worldwide net sales performance.
RedHill's Strategic Shift Toward Late-Stage Pipeline
RedHill is reshaping its portfolio to focus on higher-value opportunities. The company is advancing opaganib for Ebola-related conditions and radiation indications. It also has RHB-102, RHB-204, and RHB-107 in late-stage development across gastrointestinal and infectious disease indications. This pivot aims to accelerate RedHill's path to profitability with more targeted products.
Deal Includes Non-Compete and Transition Support
The agreement includes a five-year non-compete covenant in the United States. Apotex and RedHill also signed a six-month transition services deal to ensure a smooth handoff of Talicia operations. GuruFocus reported the transaction closed after being announced on August 31, 2026, marking a complete separation of the H. pylori business from RedHill.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
27
Reach
41
A
AnonymousAuthor
